Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing

Hyperekplexia Clinical Trial

Official title:

Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01476514
• Other study ID #: 131/11
• Secondary ID: SPUM no. 33CM30_
• Status: Terminated
• Phase: N/A
• First received: November 2, 2011
• Last updated: September 3, 2014
• Start date: October 2011
• Est. completion date: December 2012

Study information

• Verified date: September 2014
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

Mutations in genes affecting pain transmission start to be known, the investigators are investigating a mutation in a glycine channel, which has an influence on pain modulation. Pain modulation is the ability of the central nervous system to enhance or diminish the sensation of pain. The investigators therefore will test patients and healthy volunteers with quantitative sensory tests, basically determining the point at which a stimulation just starts to induce pain. These tests are reliable and permit a direct comparison between healthy volunteers and patients with the affected glycine gene.

Description:

Background

Hyperekplexia, also known as hereditary startle disease or stiff baby syndrome, is a rare neurogenetic non-epileptic disorder characterized by exaggerated persistent startle response and neonatal hypertonia to unexpected auditory, somatosensory and visual stimuli. Startle responses and generalized muscle stiffness both gradually subside during the first months of life. Pathological startle responses can remain throughout adulthood resulting in unprotected falls and injury.

Hereditary hyperekplexia has been identified in 70 pedigrees, most of them being characterized by the major form. Some occasional occurrence of the minor form was described in rare families, but its presence may remain clinically undetected.

The clinical diagnosis of the major form of hyperekplexia needs three mandatory features:

1. Generalized stiffness after birth normalizing during the first years of life

2. Excessive startling to an unexpected stimulus, particularly auditory, present from birth and remaining throughout life

3. Generalized stiffness after a startle reflex that lasts a few seconds Five genes are associated with hyperekplexia, the disease being caused by mutations in the genes encoding different subunits of the inhibitory postsynaptic glycine receptor GLRA1 and GLRB. Additionally defects in the presynaptic glycine transporter gene (SLC6A5) have been recently identified in human hyperekplexia. GPHN, encoding the glycinergic clustering molecule gephyrin, and ARHGEF9, an X-linked gene encoding collybistin, are each associated with one known case of hyperekplexia.

The glycine receptor is a member of the pentameric ligand-gated ion channel family. The receptor is a membrane-embedded protein that contains an integral Cl- -selective pore. The glycine receptor is the major determinant of inhibitory neurotransmission in the retina, spinal cord and brainstem.

Inhibitory synaptic transmission in the spinal cord dorsal horn use GABA and glycine as their principle fast neurotransmitters. Both of them open the Cl- -channels, which induce postsynaptic hyperpolarisation and impairs the propagation of excitatory potentials on dendrites of neurons. Immunofluorescence studies have revealed abundant glycinergic innervations in the dorsal horn, site attributed to the long standing gate control theory of pain. According to this model, inhibitory GABAergic and glycinergic interneurons in the superficial spinal dorsal horn are key components in the control of pain transmission from the periphery to the brain. The model states that a non-painful stimulation is felt as non painful as long as the synaptic GABAergic and glycinergic inhibition remains intact.

Pharmacological blockade of GABAergic and/or glycinergic neurotransmission in the dorsal horn mimics many symptoms of inflammatory and neuropathic pain. Additionally, a loss of synaptic inhibition in the dorsal horn occurs in animal models of experimental pain. This is difficult to prove experimentally in humans, although studies on nociceptive long term potentiation suggest that loss of inhibitory interneurons in the dorsal horn may have a role in the development of chronic pain in patients.

Objective

The aim of this study is to evaluate for the first time in humans whether symptomatic mutations in the glycinergic system affect central pain processing. Positive results would be suggestive for an important role of the glycinergic system in pain modulation and would therefore stimulate further developments for the pharmacological modulation of human pain syndromes.

Methods

Design Assessment of pain thresholds in consecutive hyperekplexia patients and a group of sex and age-matched healthy volunteers.

Subjects We will test consecutive patients with one of the five mutations cited in the introduction. Patients will receive a compensation of 150 Swiss Francs for their participation, plus reimbursement of travel costs.

23 hyperekplexia patients will be recruited. Once the testing of these patients is completed, 45 healthy age and sex-matched controls will be enrolled.

Treatment with a GABA-agonist (mainly clonazepam) will not be discontinued for safety reasons .

Pain tests:

Pressure pain detection threshold (primary outcome) Electric pain detection threshold to single cutaneous and temporal summation to repeated electrical stimulation Heat and cold pain detection, conditioned pain modulation

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 7 Years and older

Eligibility

Inclusion Criteria:

• Hyperekplexia

• GLRA1

• GLRB

• SCLA5

• GPHN

• Gephyrin

• ARHGEF9

Exclusion Criteria

• Age below 7 years

• Pregnancy

• Breast feeding

• Ongoing medication

• Cognitive impairment

Study Design

Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hyperekplexia
• Stiff-Person Syndrome

Intervention

Other:
• No intervention
The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.

Locations

Country	Name	City	State
Switzerland	Dep. of Anesthesia and Pain medicine, Bern University Hospital	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

References & Publications (4)

Andermann F, Keene DL, Andermann E, Quesney LF. Startle disease or hyperekplexia: further delineation of the syndrome. Brain. 1980 Dec;103(4):985-97. — View Citation

Müller F, Heinke B, Sandkühler J. Reduction of glycine receptor-mediated miniature inhibitory postsynaptic currents in rat spinal lamina I neurons after peripheral inflammation. Neuroscience. 2003;122(3):799-805. — View Citation

Praveen V, Patole SK, Whitehall JS. Hyperekplexia in neonates. Postgrad Med J. 2001 Sep;77(911):570-2. Review. — View Citation

Zhou L, Chillag KL, Nigro MA. Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 2002 Oct;24(7):669-74. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pressure pain detection threshold measured in kPA, measured with electronic pressure algometer applied at the centre of the pulp of the 2nd toe	Pain detection thresholds will be measured with an electronic pressure algometer applied at the center of the pulp of the 2nd toe. The probe has a surface area of 1 cm2. The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa. Pain detection threshold is defined as the point at which the pressure sensation turns to pain. The subjects are instructed to press a button when these points are reached. The algometer displays the pressure intensity at which the button is pressed.	Within 0 to 33 seconds after the beginning of the stimulation	No
Secondary	Electric pain reflex, as measured with electromyography from the biceps femoris and the rectus femoris muscles	Electromyographic (EMG) reflex responses to electrical stimulation will be recorded from the middle of the biceps femoris and the rectus femoris muscles (Ag/AgCl-electrodes). A 25 ms, train-of-five, 1 ms, square-wave impulse (perceived as a single stimulus), will be delivered. The current intensity will be increased from 1 mA in steps of 1 mA until: 1) a biceps femoris reflex with an amplitude exceeding 20 mV for at least 10 ms in the 50-150 ms post-stimulation interval will be detected (single stimulus reflex threshold); and 2) a pain sensation will be evoked (single stimulus pain threshold).	Within 50 to 150 ms after the beginning of stimulation	No
Secondary	Heat and cold pain detection thresholds, as measured with a thermode in degrees Celsius	A thermode will be applied to the skin. The temperature of the thermode will be continuously increased from 30 ºC to a maximum of 50.5 ºC at a rate of 1.5 ºC/s. Pain detection threshold is defined as for pressure stimulation. The subjects are instructed to press a button when this point is reached. For cold stimulation, the temperature of the thermode will be continuously decreased from 30 ºC to a minimum of 0 ºC at a rate of 1.5 ºC/sec. Pain detection threshold is defined as for pressure stimulation. The subjects are instructed to press a button when this point is reached.	Within 0 to 14 seconds after the beginning of the stimulation	No
Secondary	Ice water pain threshold of the hand as measured in seconds the hand was left in the water, measured with ice water container	The device consists of a container separated into an outer and an inner part by a mesh screen. The mesh screen prevents direct contact between the ice (placed in the outer part) and the hand of the subject (placed in the inner part). The water is regularly mixed to maintain the temperature in the inner part near to 0°C. The subject places his hand, wide open and to the wrist, into the inner part of the container. He is asked to keep it in the water until he feels an intolerable sensation of pain and is forced to remove his hand from the container, in any case for a maximum time of 2 min.	Within 0 to 2 minutes after the beginning of the stimulation	No
Secondary	Pressure pain detection threshold measured in kPA, measured with electronic pressure algometer applied at the centre of the pulp of the 2nd toe	Pain detection thresholds will be measured with an electronic pressure algometer applied at the center of the pulp of the 2nd toe. The probe has a surface area of 1 cm2. The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa. Pain detection threshold is defined as the point at which the pressure sensation turns to pain. The subjects are instructed to press a button when these points are reached. The algometer displays the pressure intensity at which the button is pressed.	At the end of the experiment, expected to be after 30 minutes on average	No